期刊文献+

溶血磷脂酸与急性脑梗死患者颈动脉斑块超声学特征相关性分析 被引量:3

Relationship between lysophosphatidic acid and the color Doppler ultrasonography data of carotid artery plaque of cerebral infarction patients
下载PDF
导出
摘要 目的探讨溶血磷脂酸(LPA)与急性脑梗死患者颈动脉粥样硬化(CAS)斑块超声学特征的关系。方法选择发病3 d以内的急性脑梗死患者123例,分为无斑块组、硬斑块组和软斑块组。选择同期住院的非缺血性脑血管病患者50例为对照组,所有研究对象均进行颈动脉超声检查及LPA水平测定。结果脑梗死组LPA水平较对照组明显增高,CAS斑块总检出率及软斑块检出率高于对照组,软斑块组LPA水平高于硬斑块组和无斑块组,差异有显著性。结论脑梗死患者CAS斑块发生率高,斑块组成以不稳定的软斑块居多;LPA水平与软斑块关系密切。 【Objective】 To investigate the relationship between the concentration of lysophosphatidic acid(LPA) in blood and the color Doppler ultrasonography data of carotid artery sclerosis(CAS) plaque of cerebral infarction(CI) patients.【Methods】 A total of 123 patients who were diagnosed as cerebral infarction within 3 days were divided into 3 groups: non-plaque group,hard plaque group and soft plaque group.Another group of 50 patients who were hospitalized for non-ischemic cerebrovascular diseases were selected as controls.In all the subjects the level of lysophosphatidic acid was detected and carotid artery color Doppler ultrasonography was performed.【Results】 The level of LPA in the patients of the CI group was significantly higher than that in the control group(P〈 0.05).The rates of overall plaques and soft plaques of the CI group were significantly higher than those of the control group.The level of LPA in the soft plaque group was significantly higher than those in the non-plaque group and hard plaque group.【Conclusion】 The rate of CAS plaques is high in CI patients.Most of the plaques are soft ones.The level of LPA is correlated with soft plaques.
出处 《中国现代医学杂志》 CAS CSCD 北大核心 2010年第23期3623-3625,3628,共4页 China Journal of Modern Medicine
关键词 急性脑梗死 溶血磷脂酸 颈动脉粥样硬化斑块 cerebral infarction lysophosphatidic acid carotid artery sclerosis plaque
  • 引文网络
  • 相关文献

参考文献10

  • 1BOTS ML, GROBBEE DE. Intima-media thickness as a surro- gate marker for generalised atherosclerosis [J]. Cardiovasc Drugs and Therapy, 2002, 16(4): 341-351.
  • 2HUA Y. Practical Carotid Artery and Cerebrai Vascultrasoud Di- agnostics[M]. Beijing: Science Press, 2002: 179. Chinese.
  • 3YE X, ISHII I, KINGSBURY MA, et al. Lysophosphatidic acid as novel cell survival/apoptotic factor [J]. Bioehim Biophys Acta. 2002, 1585(2-3): 108-113.
  • 4EICHHOLTZ T, JALINK K. The bioactive phospholipid lysophos- phatidie acid is released from activated platelets [J]. Biochem J. 1993, 29I(Pt 3): 677-680.
  • 5SIESSW, TIGYI G. Thrombogenic and atherogenic activities of lysophosphatidic acid[J]. Cell Biochem, 2004, 92: 1086-1094.
  • 6YE X, FUKUSHIMA N, KINGSBURY MA, et al. lysophospha- tidic acid in neural signaling [J]. Neuroreport, 2002, 13: 2169-2175.
  • 7SIESS W. Atherosclerosis and thrombogenic actions of lysophos- phatidie acid and sphingosine-1-phosphate [J]. Biochim Biophys Acts. 2002, 1582: 204-215.
  • 8JONESCB, SANE DC, HERRINGTON DM. Matrix metatlopro- teinases: a review of their structure and role in acute coronary syndrome[J]. Carcliovase Res, 2003, 59: 812-823.
  • 9RIZZA C, LEITINGERN, YUE J, etaLLysophosphatidic acid as a regulator of endothelial/leukocyte interaction [J]. Lab Invest, 1999, 79(10): 1227-35.
  • 10GRALERMH, GOETZL EJ. Lysophospholipids and their Gpro- tein-eoupled receptors in inflammation and immunity [J]. Biochim Biophys Acta, 2002, 1582(1-3): 168-174.

同被引文献24

  • 1范国洽,周亚茹,王战建.阿托伐他汀在糖尿病大血管病变中的防治作用[J].中国动脉硬化杂志,2015,23(2):196-200. 被引量:9
  • 2李振光,伍期专,唐朝枢,于占彩,王远臣,姚存姗,周慧杰,杨素国,于战涛.动脉粥样硬化患者颈动脉内膜中层厚度与血浆溶血磷脂酸含量的变化[J].中华医学杂志,2004,84(13):1071-1072. 被引量:20
  • 3李振光,于占彩,伍期专.溶血磷脂酸在动脉粥样硬化和缺血性心脑血管病中的作用[J].国外医学(脑血管疾病分册),2004,12(12):928-932. 被引量:18
  • 4Walldius G, Jungner I. The apoB/apoA-I ratio: A strong, new risk factor for cardiovascular disease and a target for lipid-lowering thera- py - A review of the evidence[J]. J Intern Med, 2006, 259 (5) : 493-519.
  • 5Camevale Schianea GP, Pedrazzoli R, Onolfo S, et al. ApoB/apoA I ratio is better than LDLC in detecting cardiovascular risk[ J]. Nutr Metab Cardiovas Dis, 2011, 21 (6) : 406-411.
  • 6Mughal MM, Khan MK, Demarco JK, et al. Symptomatic and a- symptomatic carotid artery plaque[ J]. Expert Rev Cardiovas Ther, 2011, 9 (10) : 1 315-330.
  • 7MarineUo E, Setacei C, Giubbolini M, et al. Lipid composition in atheromatous plaque: Evaluation of the lipid three-phase percent- age[J]. Life Sci, 2003, 72 (24) : 2 689-694.
  • 8Smith Jr. SC, Bonow RO, Hutter Jr. AM. AHA/ACC guidelines for secondary prevention for patients with coronary and other athero- sclerotic vascular disease: 2006 update [ J]. Circulation, 2006 , 113 (22): e847.
  • 9Vaverkova H. LDLC or apoB as the best target for reducing coro- nary heart disease: Should apoB be implemented into clinical prac- tice[J] ? Clinical Lipidology, 2011, 6 ( 1 ) : 35-48.
  • 10Davidson MH, Toth PP. High-density lipoprotein metabolism: po- tential therapeutic targets [ J ]. Am J Cardiol, 2007, 100 (11 SUP- PL. 1 ) : $32-$40.

引证文献3

二级引证文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部